Abstract

Retinoblastoma, a very aggressive cancer of the developing retina, initiatiates by the biallelic loss of RB1 gene, and progresses very quickly following RB1 inactivation. While its genome is stable, multiple pathways are deregulated, also epigenetically. After reviewing the main findings in relation with recently validated markers, we propose an integrative bioinformatics approach to include in the previous group new markers obtained from the analysis of a single cell line subject to epigenetic treatment. In particular, differentially expressed genes are identified from time course microarray experiments on the WERI-RB1 cell line treated with 5-Aza-2'-deoxycytidine (decitabine; DAC). By inducing demethylation of CpG island in promoter genes that are involved in biological processes, for instance apoptosis, we performed the following main integrative analysis steps: i) Gene expression profiling at 48h, 72h and 96h after DAC treatment; ii) Time differential gene co-expression networks and iii) Context-driven marker association (transcriptional factor regulated protein networks, master regulatory paths). The observed DAC-driven temporal profiles and regulatory connectivity patterns are obtained by the application of computational tools, with support from curated literature. It is worth emphasizing the capacity of networks to reconcile multi-type evidences, thus generating testable hypotheses made available by systems scale predictive inference power. Despite our small experimental setting, we propose through such integrations valuable impacts of epigenetic treatment in terms of gene expression measurements, and then validate evidenced apoptotic effects.

Highlights

  • Retinoblastoma is classified as “a paediatric ocular tumor that continues to reveal much about the genetic basis of cancer development” [1]

  • differentially expressed genes (DEG) profiles measured at three times are presented in Figure 1-A, with Fold Change (FC) fluctuating values

  • Our analyses refer to the assessment of temporal effects of DAC treatment on a retinoblastoma cell line

Read more

Summary

Introduction

Retinoblastoma is classified as “a paediatric ocular tumor that continues to reveal much about the genetic basis of cancer development” [1]. The genetic basis of the disease is originally centered on the biallelic inactivation of the RB1 gene, which is relevant to all cases involving both the heritable form and most of the non-heritable cases. This mechanism confers limitless replicative potential to retinoblasts, implying that its loss leaves the cells without chromosomal stability. The loss of expression of RB2, another member of the RB gene family, has been reported too, and it correlates with low apoptotic index and lesser differentiation in non-heritable cases [2]. Interaction with other proteins in cancer paths have been illustrated by [4]

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.